This is a working overview of DMSO stock, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-21. Anything still debated is marked as such rather than presented as settled.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
In Quercus ilex oaks, the fungus neutralizes harmful compounds from the tree's own leaf litter and transfer the nutrients back to the tree through the roots - an essential step for making certain growing conditions possible for these oaks. Another study shows that P.arhizus aided White Cover (Trifolium repens) growth in contaminated mining soils, and improved the growth as well as the mercury tolerance in these flowers by substantial amounts.
Radioactive decay (also known as nuclear decay, radioactivity, radioactive disintegration, or nuclear disintegration) is the process by which an unstable atomic nucleus loses energy by radiation. A material containing unstable nuclei is considered radioactive. Three of the most common types of decay are alpha, beta, and gamma decay. The weak force is the mechanism that is responsible for beta decay, while the other two are governed by the electromagnetic and nuclear forces. Radioactive decay is a random process at the level of single atoms. According to quantum theory, it is impossible to predict when a particular atom will decay, regardless of how long the atom has existed. However, for a significant number of identical atoms, the overall decay rate can be expressed as a decay constant or as a half-life. The half-lives of radioactive isotopes have a huge range: from nearly instantaneous to far longer than the age of the universe. The decaying nucleus is called the parent radionuclide (or parent radioisotope), and the process produces at least one daughter nuclide. Except for gamma decay or internal conversion from a nuclear excited state, the decay is a nuclear transmutation resulting in a daughter containing a different number of protons or neutrons (or both). When the number of protons changes, an atom of a different chemical element is created. There are 28 naturally occurring chemical elements on Earth that are radioactive, consisting of 35 radionuclides (seven elements have two different radionuclides each) that date before the time of formation of the Solar System.
(CH2CH2)O + RCOCl + NaI → RC(O)–OCH2CH2–I + NaCl Heating ethylene oxide to 100 °C with carbon dioxide, in a non-polar solvent in the presence of bis-(triphenylphosphine)-nickel(0) results in ethylene carbonate:
David Held (27 August 1951 – 2 March 2019) was a British political scientist who specialised in political theory and international relations; author of over twenty five scholarly academic texts and monographs. Basil Henriques Muriel Gray FRSE (born 30 August 1958) is a Scottish author, broadcaster and journalist, of Jewish ancestry. Gray has been a columnist for many publications, including Time Out magazine, the Sunday Correspondent, the Sunday Mirror, and Bliss magazine, and writes regularly for the Sunday Herald. and The Guardian. Zoë Heller author (Jewish father), daughter of screenwriter Lukas Heller; her paternal grandfather was the political philosopher Hermann Heller. Her brother is screenwriter Bruno Heller. Her sister, Lucy Heller Chief Executive of education charity Ark Noreena Hertz (born 24 September 1967) author, hosted "MegaHertz: London Calling", on SiriusXM's Insight channel and ITV News Economics Editor; wife of Danny Cohen (television executive), who previously held posts as Director of BBC Television and Controller of BBC One; from 1996 to 1997 she worked on the Middle East peace process with Palestinians, Egyptians, Israelis and Jordanians; honorary professor at University College London; Guardian op-ed writer.
=== Innate immunity === Dermal macrophages can phagocytose and digest foreign substances similar to other cell types in the mononuclear phagocyte system. They construct the mononuclear phagocyte system together with dendritic and Langerhans cells. Dermal macrophages have a distinct expression of genes to facilitate their specialisation in removing macromolecules and foreign pathogens. Therefore, they cannot infiltrate the lymph nodes because of their unique roles. For instance, the cell population near postcapillary venules expresses CD4. This specific population can produce chemokines to mediate the infiltration of neutrophils in an inflammatory response. Dermal macrophages' functions suggest their importance in the skin's innate immunity. Dermal macrophages, Langerhans cells and dendritic cells are the main types of antigen-presenting cells (APCs) in the skin. However, dermal macrophages have a relatively lower influence on antigen-presenting than other APCs. Thus, dermal macrophages mainly serve as phagocytes in removing foreign substances.
Sources: en.wikipedia.org
On 23 February 1848 Premier François Guizot's cabinet resigned, abandoned by the petite bourgeoisie, on whose support they thought they could depend. The heads of the more left-leaning conservative-liberal monarchist parties, Louis-Mathieu Molé and Adolphe Thiers, declined to form a government. Odilon Barrot accepted, and Thomas Robert Bugeaud, commander-in-chief of the first military division, who had begun to attack the barricades, was recalled. In the face of the insurrection that had now taken possession of the whole capital, King Louis-Philippe abdicated in favor of his nine-year-old grandson, Prince Philippe, Count of Paris, but under pressure from insurgents who invaded the chamber of the Chamber of Deputies, leaders leaned in favor of the insurrection and prepared a provisional government; a (second) republic was then proclaimed by Alphonse de Lamartine.
=== Build === Though Neanderthals are often imagined as short and stocky, they were on average the same height as pre-industrial Europeans, or even slightly taller. The body mass index of the average European Neanderthal was comparable to 20th century Canadians and Americans. Neanderthal body size varied by location; West Asian Neanderthals were taller and more slightly built than European Neanderthals. In a sample of 45 Neanderthal long bones from 14 men and 7 women, the average height was 164 to 168 cm (5 ft 5 in to 5 ft 6 in) for males and 152 to 156 cm (5 ft 0 in to 5 ft 1 in) for females. The fossil record shows that adult Neanderthals varied from about 147.5 to 177 cm (4 ft 10 in to 5 ft 10 in) in height. The average male body mass index was 26.9–28.3. Neanderthal pelvic bones were extremely wide; with Neanderthal male hips being approximately 31% wider than those of modern humans males. As in all archaic species, there is no evidence of sexual dimorphism in the Neanderthal pelvis; both males and females had large pelvic bones relative to their body size, with larger males having the largest pelvises. The Neanderthal chest was deep and wide, with a proportionally expansive thoracic cavity, and possibly stronger lung performance. and much higher caloric demands. The limbs are proportionally short. The body plan has traditionally been explained as a "hyper-arctic" adaptation (Allen's rule). Neanderthals would also have been effective sprinters: stronger lungs, and shorter limbs would have boosted efficiency.
Fossils attributable to the genus Ginkgo first appeared in the Middle Jurassic. The genus Ginkgo diversified and spread throughout Laurasia during the Jurassic and Early Cretaceous. The Ginkgophyta declined in diversity as the Cretaceous progressed, and by the Paleocene, Ginkgo adiantoides was the only Ginkgo species left in the Northern Hemisphere, while a markedly different (and poorly documented) form persisted in the Southern Hemisphere. Along with that of ferns, cycads, and cycadeoids, the species diversity in the genus Ginkgo drops through the Cretaceous, at the same time the flowering plants were on the rise; this supports the hypothesis that, over time, flowering plants with better adaptations to disturbance displaced Ginkgo and its associates. At the end of the Pliocene, Ginkgo fossils disappeared from the fossil record everywhere except in a small area of central China, where the modern species survived.
=== United States === Since a 1972 law, government insurance (Medicare) covers the cost of dialysis and transplants for citizens of any age with end stage renal disease. By 2014, more than 460,000 Americans were undergoing treatment, the costs of which amount to six percent of the entire Medicare budget. Kidney disease is the ninth leading cause of death, and the U.S. has one of the highest mortality rates for dialysis care in the industrialized world. The rate of patients getting kidney transplants has been lower than expected. These outcomes have been blamed on a new for-profit dialysis industry responding to government payment policies. A 1999 study concluded that "patients treated in for-profit dialysis facilities have higher mortality rates and are less likely to be placed on the waiting list for a renal transplant than are patients who are treated in not-for-profit facilities", possibly because transplantation removes a constant stream of revenue from the facility. The insurance industry has complained about kickbacks and problematic relationships between charities and providers.
== Deliberate targeting == A 2026 United Nations report found reasonable grounds to conclude that Palestinian children had been deliberately targeted by Israeli security forces during the conflict. The report documented cases of children being killed by single, precise gunshots by snipers and drones, frequently in the head or upper torso, suggesting a deliberate intention to target them rather than incidental harm. Doctors who had undertaken medical missions in Gaza told the Commission that it appeared Israeli Defense Force (IDF) were engaging in a "game of target practice", with different parts of children's bodies reportedly being targeted on different days. The report also documented systematic attacks on child-essential infrastructure that had contributed to preventable child deaths and long-term disabilities. The Commission further examined dehumanising rhetoric by political leaders, soldiers and public figures, which it said contributed to an environment in which violence against Palestinian children was more readily accepted.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.